Ardent Health Analysts Revise Forecasts Downward Following Disappointing Q3 Earnings
Earnings Report: Ardent Health Inc reported a loss of 17 cents per share for Q3, missing the analyst estimate of 41 cents, while sales of $1.577 billion exceeded expectations of $1.547 billion.
Guidance Revision: The company lowered its FY2025 GAAP EPS guidance from a range of $1.73-$2.01 to $0.85-$1.03.
Operational Performance: Despite the earnings miss, Ardent Health saw a 5.8% increase in admissions and a 1.4% rise in total surgeries, with revenue and adjusted EBITDA growing by 9% and 46%, respectively.
Analyst Reactions: Following the earnings announcement, Morgan Stanley downgraded the stock from Overweight to Equal-Weight, reducing the price target from $22 to $12, while Stephens & Co. maintained an Overweight rating but lowered the target from $21 to $17.
Trade with 70% Backtested Accuracy
Analyst Views on ARDT
About ARDT
About the author

- Lawsuit Background: Ardent Health, Inc. (NYSE: ARDT) is facing a securities class action lawsuit for failing to disclose uncollectible accounts in a timely manner, with allegations that it used an improper 180-day reserve period, resulting in a 33% stock price drop.
- Financial Impact: The lawsuit highlights that Ardent Health failed to accurately reflect a massive $54 million increase in professional liability reserves in its financial reports, directly affecting the company's financial transparency and investor confidence.
- Investor Action: Hagens Berman law firm has notified investors and is encouraging those who purchased ARDT shares between July 18, 2024, and November 12, 2025, to contact them by March 9, 2026, to become lead plaintiffs and seek legal remedies.
- Compliance Risks: The case reveals that Ardent Health may have intentionally delayed recognizing losses during its early public company months to maintain an artificial earnings quality profile, potentially leading to broader compliance and reputational risks.
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against Ardent Health and its executives for securities fraud, resulting in a significant 33% stock drop on November 13, 2025.
- Financial Misrepresentation: The lawsuit alleges that Ardent Health misrepresented its receivables by failing to accurately reflect its collection practices, leading to inflated accounts receivable during the reporting period, which undermines investor confidence.
- Stock Price Impact: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease and a $54 million increase in professional liability reserves, causing its stock price to plummet from $14.05 to $9.30, a decline exceeding 33%.
- Legal Consequences: Investors have until March 9, 2026, to apply to lead the case, and a favorable outcome could significantly impact Ardent Health's future financial standing.
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Ardent Health in the Middle District of Tennessee, representing investors who purchased securities between July 18, 2024, and November 12, 2025, raising serious concerns about the company's financial transparency.
- Financial Issues Exposed: The complaint alleges that Ardent Health reported inflated accounts receivable and delayed recognizing uncollectible losses, leading to investor worries about its financial health and potential impacts on future financing capabilities.
- Significant Stock Drop: On November 12, 2025, Ardent Health revealed a $43 million revenue decrease for Q3 due to revised accounts receivable collectability, causing its stock price to plummet from $14.05 to $9.30, a nearly 34% drop, reflecting market disappointment in the company's financial status.
- Investor Rights Protection: Investors must apply by March 9, 2026, to be appointed as lead plaintiffs in the lawsuit, indicating a focus on corporate governance and financial reporting, which may prompt the company to enhance its financial transparency and compliance.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, that the deadline to apply as lead plaintiff is March 9, 2026, and failure to act may result in loss of claims.
- Fee Structure: Investors joining the Ardent Health class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Ardent Health made misrepresentations regarding its accounts receivable, failing to accurately reflect their collectability, which led to investor losses following the revelation of these issues, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
- Lawsuit Background: Ardent Health is facing a securities class action lawsuit for allegedly failing to disclose its accounts receivable valuation methods, with claims that it used a 180-day cliff to maintain an artificial earnings quality profile during its early public months.
- Financial Impact: In November 2025, Ardent revealed a $42.6 million revenue cut due to a change in accounting methods and a $54 million increase in professional liability reserves, which directly triggered a 33% stock price collapse.
- Legal Liability: The lawsuit alleges that Ardent Health and its executives violated U.S. securities laws by failing to disclose insufficient professional malpractice insurance and inadequate reserves, potentially exposing investors to significant losses.
- Investor Action: Hagens Berman law firm is notifying investors that the deadline to submit claims is March 9, 2026, urging affected investors to reach out for legal support.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Ardent Health, Inc. (NYSE: ARDT) for securities purchased between July 18, 2024, and November 12, 2025, urging affected investors to contact the firm by March 9, 2026.
- False Statement Allegations: The complaint alleges that Ardent made false and misleading statements regarding its reliance on 'detailed reviews of historical collections' to assess collectible accounts receivable, which misled investors and resulted in financial losses.
- Loss Recognition Delay: The company utilized a 180-day cliff policy that allowed it to delay recognizing losses on uncollectible accounts, creating a misleadingly optimistic financial outlook until the truth was revealed to the market.
- Insufficient Liability Insurance: Ardent failed to maintain adequate levels of professional malpractice liability insurance, further increasing investor risk and leading to significant financial damages once the market became aware of the company's true situation.




